Two breast cancer patients were enrolled in the high-dose cohort, receiving 7.8 × 1010 (plus three doses of IL-2) and 9 × 1010 (plus one dose of IL-2) cells with lymphodepletion. The gene discussed is IL2; the disease is breast carcinoma.